Caporali, R., Ravasio, R., Raimondo, P. and Salaffi, F. 2021. Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy. Global and Regional Health Technology Assessment. 8, 1 (Jul. 2021), 69–79. DOI:https://doi.org/10.33393/grhta.2021.2267.